Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics

PURPOSE: Assessment of non-clinical safety signals relies on understanding species selectivity of antibodies. This is particularly important with antibody–drug conjugates, where it is key to determine target-dependent versus target-independent toxicity. Although it appears to be widely accepted that...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis Phillips, Gail, Guo, Jun, Kiefer, James R., Proctor, William, Bumbaca Yadav, Daniela, Dybdal, Noel, Shen, Ben-Quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763818/
https://www.ncbi.nlm.nih.gov/pubmed/34708303
http://dx.doi.org/10.1007/s10549-021-06427-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763818/
https://www.ncbi.nlm.nih.gov/pubmed/34708303
http://dx.doi.org/10.1007/s10549-021-06427-w

Ejemplares similares